重组结核杆菌融合蛋白（EC） | China Drugs ListRecombinant Mycobacterium tuberculosis fusion protein (EC) | China Drugs List
本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。
- 药品类型
- 生物药Biologic
- 治疗领域
- 预防与诊断Prevention & diagnosis
- 公开来源记录的适应症
- 本品适用于结核杆菌感染诊断,推荐用于6月龄及以上婴儿、儿童及65周岁以下成人。 本品皮试结果不受卡介苗(BCG)接种的影响,可用于辅助结核病的临床诊断。Diagnosis of Mycobacterium tuberculosis infection. Recommended for infants and children aged 6 months or older and adults under 65 years of age. The skin-test result is not affected by BCG vaccination, and the product can assist the clinical diagnosis of tuberculosis.
- 适应症来源与口径
- 来源日期： 2024, 2026. 适应症转录自国家医保局公开的企业申报资料；不代表已核实完整的现行说明书。Source date(s): 2024, 2026. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label.
- 说明书信息局限
- 尚未取得可核实的完整药品说明书。现有批准记录或国家医保局申报资料支持所示适应症；最新完整范围尚待确认。A verifiable complete prescribing-information document has not yet been obtained. Available approval records or NHSA submissions support the indications shown; the latest full scope needs confirmation.
- 中国可获得性状态
- 已核实中国历史批准记录；尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- 海外状态
- 待逐一核查各市场。Market-by-market verification pending.
- 医保分类
- 已纳入国家医保（乙类）Included in national insurance (Category B)
- 医保版本
- 2025版；2026年1月1日起执行2025 edition; effective 1 January 2026
- 医保限制
- 该目录条目未另列限定；仍须遵守目录凡例及法定适应症No additional restriction is specified for this formulary entry. General formulary rules and legally approved indications still apply.
- 医保期限
- 2025-01-01 至 2026-12-312025-01-01 to 2026-12-31
- 医保核查说明
- 按成分／剂型名称精确或标准化匹配。报销仍取决于剂型及目录所列支付限制。Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.